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بروتوكالت التخدير العام للمرضى الذين خيضعون للعالج باجللسات الكهربائية
حتليل اسرتجاعي لـ 504 جلسة خالل مدة مخس سنوات يف مستشفى رعاية ثالثية يف عمان
ارفيند ناريان, �ضندر الل, حمد ال�ضناوي
abstract: Objectives: This study aimed to review general anaesthesia protocols for patients undergoing 
electroconvulsive therapy (ECT) at a tertiary care hospital in Oman, particularly with regards to clinical profile, 
potential drug interactions and patient outcomes. Methods: This retrospective study took place at the Sultan 
Qaboos University Hospital (SQUH), Muscat, Oman. The electronic medical records of patients undergoing ECT 
at SQUH between January 2010 and December 2014 were reviewed for demographic characteristics and therapy 
details. Results: A total of 504 modified ECT sessions were performed on 57 patients during the study period. 
All of the patients underwent a uniform general anaesthetic regimen consisting of propofol and succinylcholine; 
however, they received different doses between sessions, as determined by the treating anaesthesiologist. Variations 
in drug doses between sessions in the same patient could not be attributed to any particular factor. Self-limiting 
tachycardia and hypertension were periprocedural complications noted among all patients. One patient developed 
aspiration pneumonitis (1.8%). Conclusion: All patients undergoing ECT received a general anaesthetic regimen 
including propofol and succinylcholine. However, the interplay of anaesthetic drugs with ECT efficacy could not be 
established due to a lack of comprehensive data, particularly with respect to seizure duration. In addition, the impact 
of concurrent antipsychotic therapy on anaesthetic dose and subsequent complications could not be determined.
Keywords: General Anesthesia; Propofol; Succinylcholine; Electroconvulsive Therapy; Drug Interactions; Oman.
امللخ�ص: الهدف: تهدف هذه الدرا�ضة ملراجعة بروت�ك�الت التخدير للمر�ضى الذين يخ�ضع�ن للعالج باجلل�ضات الكهربائية يف م�ضت�ضفى 
رعاية ثالثة مرجعي ب�ضلطنة عمان, مع مراعاة التاريخ املر�ضي وال�رسيري للمر�ضى والنتائج املحتملة لتفاعالت االدوية. الطريقة: اأخذت 
الدرا�ضة من امللفات االلكرتونية لل�ضجل الطبي للمر�ضى الذين يتلق�ن العالج باجلل�ضات الكهربائية يف م�ضت�ضفى جامعة ال�ضلطان قاب��ص 
بعمان مع اأخذ التفا�ضيل الدمي�غرافية للمر�ضى والتاريخ املر�ضي خالل الفرتة بني يناير 2010م اإىل دي�ضمرب 2014م. النتائج: اأجريت 
504 جل�ضة كهربائية لـ 57 مري�ص خالل فرتة الدرا�ضة خ�ضع فيها املر�ضى لنظام م�حد للجل�ضات الكهربائية مع تخدير عام م�حد مك�ن 
واملتتابعة على ح�ضب حتديد طبيب  املختلفة  اجلل�ضات  االأدوية بني  لهذه  تلقيهم جرعات خمتلفة  وال�ضك�ضينيل مع  الربب�ف�ل  اأدوية  من 
الدم  املت�ضارعة و�ضغط  القلب  لعامل حمدد. وكانت دقات  تعزى  ال�احد  للمري�ص  اجلل�ضات  املختلفة بني  تلك اجلرعات  تكن  التخدير. مل 
املرتفع وا�ضحة كاأحد امل�ضاعفات التي حتدث قبل اإجراء العالج باجلل�ضات الكهربائية بني املر�ضى. تعر�ص اأحد املر�ضى للتهاب رئ�ي 
)%1.8(. اخلال�صة: ح�ضل جميع املر�ضى الذين تعر�ض�ا للعالج باجلل�ضات الكهربائية على نظام م�حد للتخدير العام مك�ن من الربوب�ف�ل 
وال�ضك�ضينيل. مع هذا ال ميكن احلكم على تاثري اأدوية التخدير وفاعلية العالج باجلل�ضات الكهربائية لعدم وج�د معل�مات كافية اأو معرفة 
لتاأثريها على مدة الذهان احلا�ضلة خالل فرتة تلقي العالج. باال�ضافة اإىل اأنه مل تت�ضح الروؤية لتاثري اأدوية عالج الذهان التي يتلقاها 
املري�ص مع جرعات التخدير و امل�ضاعفات احلا�ضلة.
الكلمات املفتاحية: التخدير العام؛ الربب�ف�ل؛ ال�ضكي�ضنيل؛ العالج باجلل�ضات الكهربائية؛ تفاعل االدوية؛ عمان.
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Advances in Knowledge
- To the best of the authors’ knowledge, this study is the first to evaluate anaesthesia protocols among patients undergoing modified 
electroconvulsive therapy (ECT) in Oman.
Application to Patient Care 
- Correlating antipsychotic and anaesthetic drug protocols with the quality and duration of ECT-induced seizures may help caregivers 
choose more suitable pharmaceutical agents.
- The findings of the current study may help in creating standard protocols for the safe administration of anaesthetic agents during 
ECT treatment. 
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In clinical practice, the concept ofinducing convulsions was first introduced in 1934 when camphor oil was used to induce convulsions 
in a patient with catatonic schizophrenia; electrically-
induced seizures were subsequently reported in 
1938.1–6 In 1951, the use of general anaesthesia with 
muscle relaxants during electroconvulsive therapy 
(ECT) was proposed to alleviate the adverse effects 
and injuries resulting from seizure-induced motor 
activity, such as tongue biting and long bone 
fractures.7 Currently, performing ECT on a patient 
without anaesthesia is considered unethical.8 During 
ECT sessions, anaesthesiologists provide diligent 
cardiorespiratory monitoring services, life support 
expertise and the pharmacological reduction of actual 
seizures while allowing unimpeded electrical activity.9 
Globally, anaesthesia protocols during ECT proc-
edures are not standardised, primarily due to the 
varying availability of drugs and the preferences of 
individual anaesthetic care providers.10 However, the 
increasing number of psychopharmaceutical drugs 
available necessitates greater vigilance with regards 
to possible interactions with anaesthetic agents 
so as to avoid the development of cardiovascular 
complications.11 Moreover, the expanding geriatric 
population worldwide and the increasing burden 
of chronic diseases like diabetes, hypertension and 
ischaemic heart disease are also added risk factors 
for the increased incidence of adverse effects and 
drug interactions due to anaesthesia and ECT. A 
thorough understanding of pre-existing medical 
conditions is needed when determining the selection 
of suitable anaesthetic drugs, monitoring options 
and management of complications arising from 
anaesthesia and induced seizures.12 Anaesthetic drugs 
alone should not cause added complications or 
attenuate the efficacy of the seizure therapy.13
It is imperative for anaesthesia care providers to 
refine management strategies and treatment regimens 
for patients undergoing ECT sessions, thus ensuring 
the safety and comfort of the patient and enhancing 
overall acceptance of ECT. This study aimed to 
analyse the anaesthesia protocols used during 
modified ECT sessions at a tertiary care hospital 
in Oman over a five year period and determine 
patient outcomes, periprocedural complications and 
potential correlations with demographic, clinical, 
pharmacological and therapeutic factors. By identifying 
potential deficits in existing anaesthesia protocols, 
more objective anaesthetic and psychopharmaceutical 
treatment plans can be determined, which could then 
be extended into a region-based standard of care.
Methods
This retrospective study was conducted at the Sultan 
Qaboos University Hospital (SQUH), Muscat, Oman. 
The electronic medical records of all patients receiving 
ECT at SQUH between January 2010 and December 
2014 were analysed. Information was collected 
regarding demographic characteristics, psychiatric 
diagnosis, the presence of any comorbidities at the time 
of ECT treatment, physical status as per American 
Society of Anaesthesiologists (ASA) classifications, 
overall number of ECT sessions performed and type 
of anaesthetic drugs used during the ECT session.14 
Patients with critical illnesses or with ASA grades of 
≥III were deemed unfit for ECT and excluded from 
the study. 
All of the patients were assessed the day before 
the ECT session by a trained anaesthesiologist. Any 
use of antipsychotic drugs for primary behavioural 
disorders was documented, especially with regards 
to concomitant use immediately preceding the ECT 
session. Additional sedative premedication was not 
prescribed by the anaesthesiologist for any patient. 
The ECT procedures were conducted in the operation 
theatre recovery room by a behavioural medicine 
specialist, an anaesthesiologist and an anaesthesia 
nurse. A complete set of resuscitation equipment and 
drugs along with a piped oxygen supply and central 
suction unit were available on-hand. Before induction 
of the anaesthesia, intravenous (IV) access was 
ensured and monitoring equipment was connected. 
Bitemporal electrical shocks were delivered using a 
Thymatron® System IV Integrated ECT Instrument 
(Somatics LLC, Lake Bluff, Illinois, USA). After the 
ECT procedure, the patients were monitored until 
they were transferred to a general ward. 
Data were tabulated using an Excel spreadsheet, 
Version 2013 (Microsoft Inc., Redmond, Washington, 
USA) and analysed statistically using the Statistical 
Package for the Social Sciences (SPSS), Version 23 
(IBM Corp., Chicago, Illinois, USA). As some 
inpatients were admitted more than once, each 
admission period was considered an episode. For 
those patients receiving several sessions of mainten-
ance ECT as outpatients, these were recorded as 
sessions but not episodes. Drug dosing was inter-
preted according to kg of body weight for comp-
arative purposes.
Ethical approval for this study was granted by the 
Medical Ethics Committee of the College of Medicine 
& Health Sciences at Sultan Qaboos University (MREC 
#911). Patient confidentiality was maintained by 
coding the medical records to conceal patient identity.
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Results
During the study period, a total of 504 ECT sessions 
were performed on 57 patients, including 20 male 
and 37 female patients. Among these patients, a total 
of 71 episodes (admission periods) were noted, with 
10 inpatients having two episodes and four inpatients 
having three episodes or more. Male and female 
patients were statistically comparable in terms of 
age, weight and body mass index; however, men were 
significantly taller than women (P = 0.002). The mean 
number of ECT sessions per patient was 8.8 (range: 
2–23 sessions). The mean hospital stay duration was 
35.8 days prior to the completion of ECT treatment 
and 4.2 days after the final ECT session [Table 1]. 
Among the patients who underwent ECT during 
the study period, 34 patients (59.6%) were diagnosed 
with major depression, 10 (17.5%) with schizophrenia 
and seven (12.3%) with bipolar disorder. The remaining 
six patients (10.5%) had postpartum behavioural and/
or obsessive-compulsive disorders. The majority 
of the patients had no comorbid illnesses and were 
classified as ASA grade I (n = 45; 78.9%). There were 
12 patients (21.1%) classified as ASA grade II or III 
in terms of physical status. Six patients had a single 
systemic disease, while the remaining six had two or 
more illnesses, with the most common being diabetes, 
hypertension and controlled ischaemic heart disease 
[Table 2]. 
Table 1: Demographic and clinical variables of patients undergoing electroconvulsive therapy sessions at the Sultan 
Qaboos University Hospital, Muscat, Oman, according to gender (N = 57)
Variable Mean ± SD Inter-gender comparison
Females (n = 37) Males (n = 20) T value* Mann-
Whitney U
P value
Age in years 42.7 ± 18.9 45.1 ± 17.7 -0.470 - 0.640
Height in m 1.54 ± 0.06 1.61 ± 0.09 -3.299 - 0.002†
Weight in kg 64.9 ± 16.6 70.3 ± 19.4 1.102 - 0.275
BMI in kg/m2 27.2 ± 6.4 26.9 ± 6.6 0.131 - 0.896
ECT sessions (range) 8.9 ± 19 (4–23) 8.6 ± 21 (2–23) 0.208 - 0.836
Hospital stay in days (range) 34.5 ± 99 (8–107) 37.1 ± 58 (7–65) 0.427 - 0.671
Post-ECT hospital stay in days (range) 4.0 (0–36) 4.3 (0–17) 0.196 - 0.845
ASA status, n (%)
     Grade 1 28 (49.1) 17 (29.8) - 331 0.341
     Grade 2 5 (8.8) 3 (5.3)
     Grade 3 4 (7.0) 0 (0.0)
Propofol dose in mg/kg
     Minimum 1.36 ± 0.38 1.38 ± 0.29 - 404 0.567
     Maximum 1.94 ± 0.45 1.94 ± 0.52 - 366.5 0.953
Succinylcholine dose in mg/kg
     Minimum 0.64 ± 0.17 0.64 ± 0.15 - 369 0.986
     Maximum 0.84 ± 0.23 0.87 ± 0.26 - 379 0.879
BMI = body mass index; ECT = electroconvulsive therapy; ASA = American Society of Anaesthesiologists.
*Using t(55). †Statistically significant. 
Table 2: Prevalence of comorbid diseases among 
patients undergoing electroconvulsive therapy at the 
Sultan Qaboos University Hospital, Muscat, Oman 
(N = 57)
Comorbid illness n (%)*
Hypertension 5 (8.8)
Diabetes 4 (7.0)
Ischaemic heart disease 3 (5.3)
Liver cirrhosis 1 (1.8) 
Obesity-related sleep apnoea 1 (1.8) 
Gastric ulcer 1 (1.8) 
Chronic nephritis 1 (1.8) 
Breast carcinoma 1 (1.8) 
Hypothyroidism 1 (1.8) 
*Patients with more than one comorbid illness have been included in 
several categories.
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Every patient received between one and five 
sedative drugs before each ECT session as part of 
their psychiatric medical therapy. As numerous 
adjustments were made to the doses due to changes 
in the clinical condition of each patient, definitive 
premedication doses were not recorded. Atropine 
was not used as routine premedication for any of the 
patients. During the ECT sessions, all of the patients 
were attended by a trained staff anaesthesiologist and 
intravenously received propofol as an anaesthetic agent 
and succinylcholine as a muscle relaxant. Propofol 
doses ranged from 1.36–1.94 mg/kg with individual 
doses titrated to clinical loss of consciousness by the 
attending anaesthesiologist. Variations in dosing were 
noted between different ECT sessions for the same 
patient in subsequent episodes; however, these vari-
ations could not be attributed to any particular factor. 
Mean doses of succinylcholine ranged between 
0.64–0.87 mg/kg. Subsequent doses of succinylcholine 
during later ECT sessions for the same patient were 
tailored according to the clinical observations of 
the attending anaesthesiologist and the behavioural 
medicine team. Electrocardiography (ECG) monitor-
ing took place throughout all ECT sessions. In 
addition, pulse, heart rate, blood oxygen saturation 
and automated non-invasive blood pressure were 
monitored at regular intervals during the session.
During the ECT procedure, transient tachycardia 
and hypertension were observed in all patients, 
initially after the succinylcholine administration and 
then during the clonic phase of the seizures, following 
the initial parasympathetic activity of the tonic phase. 
Intravenous lidocaine was administered prophyl-
actically to one patient (1.8%) with a history of 
frequent premature ventricular contractions, which 
did not lead to haemodynamic instability. Table 3 
presents a summary of the peri- and postprocedural 
complications which required additional medication 
or management. Beta-blocker therapy was required 
for five patients (8.8%), although not during all ECT 
sessions for each patient. Transient bradycardia and 
hypersalivation were documented in two (3.5%) and 
four patients (7.0%), respectively; the development of 
these complications were not related to ASA grade 
severity. After the ECT procedure, glycopyrrolate was 
administered to four patients (7.0%) to reduce profuse 
oral secretions and atropine was administered to one 
patient (1.8%) due to persistent bradycardia. Another 
patient with a pre-existing atrial fibrillation was 
diagnosed with bradycardia after the ECT procedure 
but did not require atropine therapy. 
Sustained seizure activity was documented in one 
patient (1.8%) classified as ASA grade I who needed an 
additional propofol dose and a higher succinylcholine 
dose in subsequent ECT sessions. One ECT session 
(0.2%) was aborted after the administration of 
anaesthetic drugs as the ECT energy delivery unit 
malfunctioned. Delayed recovery was documented 
in one patient (1.8%) classified as ASA grade I. One 
patient (1.8%) went into respiratory distress and 
oxygen desaturation after his third ECT session which 
presented within an hour of being moved from the 
recovery room. The initial diagnosis of a pulmonary 
embolism was ruled out by chest imaging and a 
subsequent diagnosis of aspiration pneumonitis was 
made, likely due to diabetes-related gastroparesis. 
The patient was given supplemental oxygen and non-
invasive ventilatory support in a high-dependency 
ward and was prescribed a five-day course of anti-
biotics. He was subsequently discharged from the 
hospital after a complete recovery. 
Anaesthetic regimens could not be correlated 
with patient outcomes. Unfortunately, information 
Table 3: Complications*, management and patient 
outcomes of electroconvulsive therapy sessions at the 
Sultan Qaboos University Hospital, Muscat, Oman 
(N = 504)




Facial flush 1 (0.2) Continuous 
monitoring
Self-limiting
Tachycardia 2 (0.4) Esmolol (50 mg) Control of 
symptom
Bradycardia 2 (0.4) Atropine (0.5 mg) Control of 
symptom




Hypertension 2 (0.4) Labetalol (10 mg) Control of 
symptom








Hyperglycaemia 1 (0.2) IV insulin 



























IV = intravenous; ECT = electroconvulsive therapy.
*Including only those complications which required additional 
medication or management.
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regarding the energy level of shocks delivered and 
seizure duration was unavailable for any of the 
patients, presumably due to equipment constraints. 
As such, the effect of the anaesthetic drugs on the 
efficacy of ECT could not be established. The effect of 
concurrent antipsychotic therapy on anaesthetic drug 
dose and subsequent complications could also not 
be determined. 
Discussion
In spite of its mechanism of action, ECT is one of 
the safest therapeutic procedures for the treatment 
of mental illness, with reported post-treatment 
mortality rates of 1:25,000–50,000.3 Nevertheless, care 
providers should remain vigilant as induced seizures 
affect the cardiorespiratory and autonomic systems; 
although transient, these physiological effects pose a 
serious hazard, particularly to elderly patients or those 
with multiple comorbidities.15 According to previous 
research, ECT is currently available in 23 Asian 
countries; however, the use of this type of therapy in 
the Asian region is considered critically suboptimal 
in terms of conduct, monitoring and training.16 
In the Middle East, objective studies of mental 
illness—and, more specifically, the use of ECT and 
associated anaesthetic regimens—have not yet been 
conducted.17 A 10-year audit of ECT treatment at 
a university hospital in Saudi Arabia is currently the 
largest body of work on this topic in the Arab region.18 
As such, to the best of the authors’ knowledge, this is 
the first study to evaluate the use of anaesthesia among 
patients undergoing ECT in Oman.
The use of anaesthetic agents during ECT, prim-
arily central nervous system (CNS) depressors which 
attenuate the intensity/duration of seizures, has been 
widely researched.19 In general, most anaesthetic 
agents depress the CNS, thus ironically countering 
the objective of ECT, which is to excite the CNS and 
induce seizures.20 Although methohexital and sodium 
thiopental were previously the most frequently used 
anaesthetic agents for ECT, these drugs have now 
been largely replaced by propofol due to its wider 
availability, faster recovery profile and favourable 
effect on haemodynamic stability, despite its effect in 
reducing seizure production.19,21 Other inhalational 
anaesthetic agents have been compared favourably 
with propofol.22 Ketamine and etomidate do not have 
anticonvulsant properties and seem to provide a 
higher quality and duration of seizures.23,24 However, 
associated side-effects such as hallucinations, symp- 
athetic activation of the nervous system and hypo-
thalamic depression have excluded their routine 
use during ECT treatment.25 Numerous adjuncts to 
induction agents have been suggested so as to reduce 
the required dose of propofol and provide good 
sedation depth and seizure quality; remifentanil, 
a novel ultra-short-acting opioid, has a favourable 
profile in this respect.26 
The current study sought to correlate concomitant 
use of antipsychotic medications with anaesthesia 
dosages during ECT sessions in order to determine 
a pattern which might allow the clinical utilisation of 
a narrower dosage range. This would eliminate dose 
variations between anaesthesiologists and be more 
objective and safe for general patient use. Concom-
itant antipsychotic drugs (e.g. benzodiazepines) have 
been implicated in raising the seizure threshold, 
thus reducing the overall efficacy of ECT; in such 
patients, cognitive function should be monitored 
on an on-going basis or at least after each ECT 
course, as recommended in the National Institute 
of Clinical Excellence guidelines.27 Unfortunately, 
the varied drug regimens and dosages and differing 
clinical conditions of the patients in the current study 
made it difficult to determine a statistical or clinical 
correlation with either anaesthetic drug dose or ECT 
efficacy. In addition, the short-acting muscle relaxant 
succinylcholine minimises physical musculoskeletal 
manifestations of induced seizures, while allowing 
seizure activity to proceed in the brain tissue.28 This 
complete attenuation of the clinical signs of a seizure 
means that the only way to record seizure duration 
is by electroencephalography (EEG). In the current 
study, seizure duration could not established either via 
clinical observation or EEG recordings, due to a lack of 
proper equipment and the absence of a specific clinical 
directive. This precluded any correlation between 
anaesthetic drug doses and attenuation of seizure 
intensity or duration. Finally, the dose of electrical 
energy delivered during ECT sessions in the current 
study was not recorded in the patients’ medical 
records. Analysis of the energy dose, in correlation 
with the seizure duration and the anaesthetic drug 
dose, would have provided a good measure of the 
efficacy and robustness of the anaesthetic regimen 
used for ECT.9 
Succinylcholine is the gold standard for modified 
ECT sessions.28 As mentioned earlier, it is recomm-
ended that the lowest possible dose of muscle 
relaxants be used so as to maintain minimal muscle 
fasciculation and obtain visual evidence of seizures.29 
The goal is to prevent massive tonic-clonic seizures 
resulting in movements that could lead to soft tissue/
bony injury, rhabdomyolysis or hyperkalemia. In 
situations where a depolarising muscle relaxant is 
contraindicated, such as with paraplegia, stroke, 
hyperkalemic syndromes and major trauma/burns, 
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rocuronium has been administered with rapid 
reversal of its neuromuscular blockade using the 
novel cyclodextrin agent sugammadex.30 Low-dose 
atropine has been advocated to counter transient 
parasympathetic-mediated dysrhythmia and increased 
exocrine secretions after ECT.31 However, given 
the arid environment and high ambient temper-
atures of the Middle East, the potential thermo-
genic action of parasympatholytic agents precludes 
their routine use as a premedication.32 Additionally, 
patients undergoing ECT are usually also prescribed 
various antipsychotic agents known to trigger the 
serotonin-mediated hypothalamic resetting of body 
temperature-control mechanisms.33 Beta-blockers 
such as esmolol or labetalol are the mainstay of 
therapy for the management of hypertension and 
tachyarrhythmia, which are usually persistent after 
ECT is administered.34 However, esmolol has a dose-
related effect of shortening the duration of a seizure, 
with minimal impact on EEG measurements. In 
comparison, the novel alpha agonist dexmedetomidine 
has been shown to more favourably reduce the 
hyperdynamic circulatory response after ECT.35 
During short anaesthesia sessions for ECT, patients 
undergo ventilation with a face mask or positive 
pressure ventilation with a bag-mask device, without 
definitive airway protection devices; this is because 
the procedure is always performed on an elective 
basis and with an adequate fasting period, obviating 
the need for such interventions. However, due 
to seizure-induced relaxation of the oesophageal 
sphincter, patients with oesophageal reflux disease 
or gastric dysmotility/gastroparesis due to diabetic 
or autonomic neuropathy are likely candidates for 
aspiration while unconscious. Hence, it is necessary 
to monitor oxygen saturation throughout the proc-
edure so as to detect possible life-threatening 
episodes of desaturation.36 Sudden cardiac death has 
also been reported following ECT, likely due to pro-
arrhythmogenic interactions between antipsychotic 
medications and the application of electrical energy; 
hence, there is a need for diligent pre-anaesthetic 
and periprocedural 12-lead ECG monitoring.37 Using 
bispectral index monitoring to determine sedation 
depth and titrate anaesthetic agents is a promising 
new technology in ensuring patient safety during ECT 
sessions.38 Novel shorter-acting adjunctive pharma-
cologic agents also need to be explored, particularly 
for patients undergoing ECT who present at an older 
age or with comorbidities.18 
A major limitation of the present study was the 
lack of documentation regarding the energy level, 
number and duration of the electric shocks delivered 
during ECT sessions, particularly with regards to 
the lack of EEG data. Moreover, the use of differing 
primary antipsychotic drug regimens in patients, 
many with additional anti-seizure activities, con-
founded attempts to identify optimum anaesthetic 
drug doses for seizure quality and duration and 
precluded more objective correlations with the 
anaesthetic drug doses used. In order to determine 
safer and more objective anaesthesia protocols, 
prospective studies are recommended to correlate 
energy levels of electric shocks delivered during ECT, 
seizure duration, concomitant antipsychotic agents 
and overall patient outcomes.
Conclusion
All ECT sessions in the current study were conducted 
using a uniform anaesthesia protocol consisting of 
propofol and succinylcholine. Wide dosage variations 
were observed among patients and between different 
sessions for the same patient. No specific factor could 
explain these variations, nor could the anaesthetic 
regimen be correlated with eventual patient outcomes. 
Increased oral secretions and transient tachycardia, 
bradycardia and hypertension were the most common 
periprocedural complications, which did not necess-
itate any major change in the anaesthetic regimen. 
Due to a lack of data with regards to the energy level, 
number and duration of the electric shocks delivered 
during ECT sessions, correlations between anaesthetic 
drugs and ECT efficacy could not be established. 
Furthermore, the impact of concurrent antipsychotic 
therapy on anaesthetic regimen and patient outcomes 
could not be determined.
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